{"id":"https://openalex.org/W2987185017","doi":"https://doi.org/10.1182/blood-2019-124475","title":"Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759","display_name":"Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2987185017","doi":"https://doi.org/10.1182/blood-2019-124475","mag":"2987185017"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-124475","doi":"https://doi.org/10.1182/blood-2019-124475","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-124475","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100824657","display_name":"Lina Han","orcid":"https://orcid.org/0009-0009-2713-5478","observed_orcids":["https://orcid.org/0009-0009-2713-5478","https://orcid.org/0009-0008-1140-5093"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lina Han","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071658726","display_name":"Antonio Cavazos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antonio Cavazos","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058898565","display_name":"Natalia Baran","orcid":"https://orcid.org/0000-0003-0618-4798","observed_orcids":["https://orcid.org/0000-0003-0618-4798"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natalia Baran","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100360359","display_name":"Qi Zhang","orcid":"https://orcid.org/0000-0002-7918-8952","observed_orcids":["https://orcid.org/0000-0002-7918-8952"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qi Zhang","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067657823","display_name":"Vinitha M. Kuruvilla","orcid":"https://orcid.org/0000-0001-5864-4640","observed_orcids":["https://orcid.org/0000-0001-5864-4640"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vinitha Mary Kuruvilla","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109442915","display_name":"Jason P. Gay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason P Gay","raw_affiliation_strings":["Institute for Applied Cancer Science and Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Applied Cancer Science and Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071445059","display_name":"Ningping Feng","orcid":"https://orcid.org/0000-0003-1917-9648","observed_orcids":["https://orcid.org/0000-0003-1917-9648"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ningping Feng","raw_affiliation_strings":["Institute for Applied Cancer Science and Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Applied Cancer Science and Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079218001","display_name":"Venkata Lokesh Battula","orcid":"https://orcid.org/0000-0001-5415-9058","observed_orcids":["https://orcid.org/0000-0001-5415-9058"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Venkata Lokesh Battula","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035605515","display_name":"Naval Guastad Daver","orcid":"https://orcid.org/0000-0001-7103-373X","observed_orcids":["https://orcid.org/0000-0001-7103-373X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naval G. Daver","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048521277","display_name":"Joseph R. Marszalek","orcid":"https://orcid.org/0000-0003-2320-3209","observed_orcids":["https://orcid.org/0000-0003-2320-3209"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph R Marszalek","raw_affiliation_strings":["Institute for Applied Cancer Science and Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Applied Cancer Science and Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079262854","display_name":"Michael Andreeff","orcid":"https://orcid.org/0000-0002-1144-1958","observed_orcids":["https://orcid.org/0000-0002-1144-1958"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Andreeff","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022647201","display_name":"Marina Y Konopleva","orcid":"https://orcid.org/0000-0002-9347-2212","observed_orcids":["https://orcid.org/0000-0002-9347-2212"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marina Y Konopleva","raw_affiliation_strings":["Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"5161","last_page":"5161"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10301","display_name":"Mitochondrial Function and Pathology","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9879999756813049},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8500000238418579},{"id":"https://openalex.org/keywords/leukemia-stem-cells","display_name":"leukemia stem cells","score":0.8040000200271606},{"id":"https://openalex.org/keywords/oxidative-phosphorylation-inhibition","display_name":"oxidative phosphorylation inhibition","score":0.7850000262260437},{"id":"https://openalex.org/keywords/iacs-010759","display_name":"IACS-010759","score":0.9390000104904175},{"id":"https://openalex.org/keywords/mitochondrial-complex-i","display_name":"mitochondrial complex I","score":0.9200000166893005},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.8130000233650208},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9490000009536743},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6269999742507935},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.7540000081062317},{"id":"https://openalex.org/keywords/reactive-oxygen-species","display_name":"reactive oxygen species","score":0.6899999976158142},{"id":"https://openalex.org/keywords/oxygen-consumption-rate","display_name":"oxygen consumption rate","score":0.8069999814033508},{"id":"https://openalex.org/keywords/mitochondrial-metabolism","display_name":"mitochondrial metabolism","score":0.47999998927116394},{"id":"https://openalex.org/keywords/leukemia-survival","display_name":"leukemia survival","score":0.33399999141693115},{"id":"https://openalex.org/keywords/bioluminescence-imaging","display_name":"bioluminescence imaging","score":0.5789999961853027},{"id":"https://openalex.org/keywords/oci-aml3","display_name":"OCI-AML3","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C57600042","wikidata":"https://www.wikidata.org/wiki/Q227564","display_name":"Oxidative phosphorylation","level":2,"score":0.6296316385269165},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.5812204480171204},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5721184611320496},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.5598252415657043},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5079424977302551},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.5028843283653259},{"id":"https://openalex.org/C28859421","wikidata":"https://www.wikidata.org/wiki/Q39572","display_name":"Mitochondrion","level":2,"score":0.4909360706806183},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4619678854942322},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.286194771528244},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.23773542046546936},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.19374939799308777}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-124475","doi":"https://doi.org/10.1182/blood-2019-124475","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-124475","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4367602571","https://openalex.org/W4389232189","https://openalex.org/W2556459726","https://openalex.org/W2605757478","https://openalex.org/W2405807065","https://openalex.org/W2337932627","https://openalex.org/W3045101952","https://openalex.org/W3081275729","https://openalex.org/W2985901894","https://openalex.org/W3090943432"],"abstract_inverted_index":{"Acute":[0],"myeloid":[1],"leukemia":[2,12,264,314,346,372,403,407],"(AML)":[3],"is":[4,544],"initiated":[5],"and":[6,19,33,65,93,103,138,165,184,210,239,276,368,405,427,450,459,549,552],"maintained":[7],"by":[8,227,429,480,485,520],"a":[9,81,319,335,399,575,581],"relatively":[10],"rare":[11],"stem":[13],"cells":[14,38,67,100,129,149,315,363,455,529],"(LSCs)":[15],"capable":[16],"of":[17,72,98,121,158,234,311,324,331,392,413,432,446,473,506,570,574,584,593,601,631,736,748,761,776,789,800,812,828,860],"self-renewal":[18],"proliferation.":[20],"Recent":[21],"data":[22,438,442,560],"showed":[23],"that":[24,80,216,301],"LSCs":[25,64,449,474,492,548],"(Lagadinou":[26],"et":[27,45,107],"al.":[28,46,108],"Cell":[29,31],"Stem":[30],"2013)":[32],"residual":[34,41,127,326,361,527],"cytarabine":[35],"(Ara-C)-resistant":[36],"AML":[37,66,99,128,142,322,337,362,448,528,587],"(representing":[39],"minimal":[40,325,526],"disease,":[42],"MRD)":[43],"(Farge":[44],"Cancer":[47,596,604,805,840],"Discovery":[48],"2017)":[49],"are":[50],"highly":[51],"dependent":[52],"on":[53,126,172,273,313,384,423,533,627,732,744,757,772,785,796,808,824,856],"mitochondrial":[54,88,163,174,219],"function":[55],"for":[56,535,562,567,818],"survival.":[57,536],"This":[58],"unique":[59],"metabolic":[60],"biology":[61],"makes":[62],"chemoresistant":[63],"vulnerable":[68],"to":[69,117,196,271,287,469],"pharmacological":[70],"blockade":[71],"the":[73,96,119,173,232,288,309,515],"oxidative":[74],"phosphorylation":[75],"(OXPHOS).":[76],"We":[77,306],"have":[78],"reported":[79],"novel":[82],"OXPHOS":[83,92,122,201,228,534,537],"inhibitor":[84,542],"IACS-010759":[85,125,203,236,312,395,521,543,564,585],"potently":[86],"inhibits":[87,95],"complex":[89,540],"I,":[90],"suppresses":[91],"selectively":[94],"growth":[97],"in":[101,104,135,153,180,221,248,266,318,356,364,380,452,456,488,500,546,553,557,580,586],"vitro":[102,154],"vivo":[105],"(Molina":[106],"Nat":[109],"Med":[110],"2018).":[111],"In":[112,198,464,524],"this":[113],"study,":[114],"we":[115,250],"aimed":[116],"determine":[118],"effects":[120],"inhibition":[123,538],"with":[124,145,151,202,254,334,342,394,514,539,555,565],"surviving":[130,316,530],"standard":[131,240],"chemotherapy":[132,217,241,317,466,531,556,566],"(Doxorubicin/Ara-C,":[133],"DA)":[134],"cell":[136],"line":[137],"patient-derived":[139],"xenograft":[140],"(PDX)":[141],"models.":[143],"Consistent":[144],"our":[146],"hypothesis,":[147],"OCI-AML3":[148],"treated":[150],"DA":[152,343,414],"induced":[155,519],"elevated":[156],"levels":[157],"reactive":[159],"oxygen":[160,186,517],"species,":[161],"higher":[162],"mass":[164,436],"membrane":[166],"potential":[167],"(Fig.":[168,279,294,328,415,439,462],"1A),":[169],"indicating":[170],"reliance":[171],"metabolism.":[175],"Further,":[176],"Ara-C":[177],"treatment":[178,292,391],"resulted":[179],"significantly":[181,262,283,470],"increased":[182],"basal":[183,209],"maximal":[185],"consumption":[187,518],"rates":[188],"(OCR)":[189],"(36%\u00b18%,":[190],"p=0.03;":[191],"36%\u00b13%,":[192],"p=0.003,":[193],"respectively)":[194],"compared":[195,270,286],"control.":[197],"turn,":[199],"targeting":[200],"at":[204],"30":[205],"nM":[206],"fully":[207],"inhibited":[208],"Ara-C-induced":[211],"OCR.":[212],"These":[213],"findings":[214],"indicate":[215],"fosters":[218],"respiration":[220],"AML,":[222],"which":[223],"could":[224],"be":[225],"abrogated":[226],"inhibitor.":[229],"To":[230],"test":[231],"efficacy":[233,310],"combining":[235,563],"(5":[237],"mg/kg)":[238,247,397],"(Doxorubicin:":[242],"1.5":[243],"mg/kg;":[244],"Ara-C:":[245],"50":[246],"vivo,":[249],"injected":[251],"NRG":[252],"mice":[253,332,366,393],"genetically":[255],"engineered":[256],"OCI-AML3/Luc/GFP":[257],"cells.":[258],"Bioluminescent":[259],"imaging":[260],"demonstrated":[261,443],"reduced":[263,344,402,444,484],"burden":[265,347],"DA/IACS-010759":[267,281],"combination":[268,282,487,554],"group":[269],"vehicle":[272,289,501],"days":[274],"15":[275],"42":[277],"(p<0.01)":[278],"1B).":[280],"extended":[284],"survival,":[285],"or":[290,475,633,738,750,763,778,791,802,814,830,862],"single-agent":[291],"arms":[293],"1C).":[295],"Mouse":[296],"body":[297],"weight":[298],"monitoring":[299],"indicated":[300],"therapy":[302],"was":[303,420,482,511],"well":[304],"tolerated":[305],"next":[307],"examined":[308],"chemosensitive":[320],"PDX":[321,338],"model":[323],"disease":[327],"1D).":[329],"Treatment":[330],"inoculated":[333],"human":[336],"harboring":[339],"FLT3-ITD":[340],"mutation":[341],"circulating":[345],"(0.8":[348],"\u00b1":[349,353,374,378,494,498],"0.6%":[350],"vs":[351,376,496],"45.8":[352],"8.2%":[354],"blasts":[355],"vehicle-treated":[357,381],"mice,":[358,382],"p=0.001).":[359],"The":[360,441,504,591],"DA-treated":[365],"expanded":[367],"caused":[369],"rapidly":[370],"progressive":[371],"(78.2":[373],"6.2%":[375],"95.3":[377],"1.0%":[379],"p=0.047)":[383],"week":[385],"6":[386,874],"post":[387,411],"DA.":[388],"Daily":[389],"oral":[390],"(7.5":[396],"as":[398],"single":[400],"agent":[401],"burden,":[404],"delayed":[406],"recurrence":[408],"when":[409],"administered":[410],"completion":[412],"1E).":[416],"A":[417],"SPADE":[418],"tree":[419],"built":[421],"based":[422],"13":[424],"surface":[425],"markers":[426],"colored":[428],"expression":[430,505],"intensity":[431],"CD34":[433],"using":[434],"CyTOF":[435],"cytometry":[437],"1F).":[440],"frequency":[445],"CD34+CD38lowCD123+":[447],"increase":[451],"CD11c+":[453],"differentiated":[454],"both":[457],"IACS":[458],"IACS/DA":[460,486],"groups":[461],"1G&H).":[463],"contrast,":[465],"alone":[467,551],"failed":[468],"reduce":[471],"fractions":[472],"induce":[476],"differentiation.":[477],"Proliferation":[478],"measured":[479],"Ki67":[481],"greatly":[483],"all":[489],"populations":[490],"including":[491],"(1.4":[493],"0.3%":[495],"5.5":[497],"0.4%":[499],"group,":[502],"p<0.01).":[503],"Hypoxia-Inducible":[507],"Factor":[508],"1\u03b1":[509],"(HIF-1\u03b1)":[510],"downregulated,":[512],"consistent":[513],"decreased":[516],"(not":[522],"shown).":[523],"conclusion,":[525],"depend":[532],"I":[541],"effective":[545],"reducing":[547],"MRD,":[550],"vivo.":[558],"Our":[559],"advocate":[561],"improved":[568],"control":[569],"MRD":[571],"upon":[572],"identification":[573],"recommended":[576],"Phase":[577],"II":[578],"dose":[579],"clinical":[582],"trial":[583],"(NCT02882321).":[588],"Disclosures":[589],"Zhang:":[590],"University":[592,600],"Texas":[594,602],"M.D.Anderson":[595,603],"Center:":[597,605],"Employment.":[598,606],"Kuruvilla:The":[599],"Kantarjian:Pfizer:":[607],"Honoraria,":[608,615,625,645,655,906,918,931,935],"Research":[609,612,616,619,622,639,642,646,649,652,656,660,668,674,678,682,688,692,697,701,707,711,715,720,723,726,782,820,834,837,841,843,891,901,907,914,919,922,932,936,939,952,956,959],"Funding;":[610,613,617,620,623,640,643,647,650,653,657,669,675,679,683,689,693,698,702,708,712,716,721,724,727,835,838,844,892,902,908,915,920,923,933,937,940,953,957],"Cyclacel:":[611],"AbbVie:":[614,916],"Daiichi-Sankyo:":[618],"Immunogen:":[621,672],"Actinium:":[624],"Membership":[626,731,743,756,771,784,795,807,823,855],"an":[628,733,745,758,773,786,797,809,825,857],"entity's":[629,734,746,759,774,787,798,810,826,858],"Board":[630,735,747,760,775,788,799,811,827,859],"Directors":[632,737,749,762,777,790,801,813,829,861],"advisory":[634,739,751,764,779,792,803,815,831,863],"committees;":[635,740,752,765,780,793,804,816,832,864],"Takeda:":[636],"Honoraria;":[637,911,926,943],"Ariad:":[638],"Novartis:":[641,705],"Agios:":[644,670,958],"BMS:":[648,680],"Astex:":[651],"Amgen:":[654,898,924],"Jazz":[658,893],"Pharma:":[659],"Funding.":[661,960],"Daver:Jazz:":[662],"Consultancy;":[663,671,685,704,718,877,879,895,897],"Hanmi":[664],"Pharm":[665],"Co.,":[666],"Ltd.:":[667],"Consultancy,":[673,677,681,687,691,696,700,706,710,714,883,905,910,917,925,930,942],"Genentech:":[676,934],"Celgene:":[684,896],"Karyopharm:":[686],"Pfizer:":[690],"Daiichi":[694,880],"Sankyo:":[695],"Sunesis:":[699],"Forty-Seven:":[703,909],"Incyte:":[709],"Abbvie:":[713],"Astellas:":[717],"Servier:":[719],"NOHLA:":[722],"Glycomimetics:":[725],"Otsuka:":[728],"Consultancy.":[729,899],"Andreeff:BiolineRx:":[730],"CLL":[741],"Foundation:":[742,842],"Leukemia":[753],"Lymphoma":[754],"Society:":[755],"NCI-RDCRN":[766],"(Rare":[767],"Disease":[768],"Cliln":[769],"Network):":[770],"German":[781],"Council:":[783],"NCI-CTEP:":[794],"UK:":[806],"Center":[817],"Drug":[819],"&":[821,885,949],"Development:":[822],"NIH/NCI:":[833],"CPRIT:":[836],"Breast":[839],"Oncolyze:":[845],"Equity":[846,849,853,866,869,872,946],"Ownership;":[847,850,867,870,873],"Oncoceutics:":[848],"Senti":[851],"Bio:":[852],"Ownership,":[854,947],"Eutropics:":[865],"Aptose:":[868],"Reata:":[871],"Dimensions":[875],"Capital:":[876],"AstaZeneca:":[878],"Sankyo,":[881],"Inc.:":[882],"Patents":[884,887,948],"Royalties:":[886],"licensed,":[888],"royalty":[889],"bearing,":[890],"Pharmaceuticals:":[894,945],"Konopleva:Calithera:":[900],"Stemline":[903],"Therapeutics:":[904],"Eli":[912],"Lilly:":[913],"Cellectis:":[921],"F.":[927],"Hoffman":[928],"La-Roche:":[929],"Ascentage:":[938],"Kisoji:":[941],"Reata":[944],"Royalties;":[950],"Ablynx:":[951],"Astra":[954],"Zeneca:":[955]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}